Who
Arie Mayer
Director
Company insider
Files Form 4 as: Director, Oramed Pharmaceuticals.
In numbers
- Trades disclosed
- 17
- Buys
- 2
- Sells
- 1
- Bought
- $20K
- Sold
- $77K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 8 Jan 2020
- Last trade
- 31 Dec 2025
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Dec 2025filed 5 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 31 Dec 2025filed 5 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,900 | filing |
| 31 Dec 2025filed 5 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 31 Dec 2025filed 5 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,900 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,975 | filing |
| 4 Jan 2024filed 8 Jan 2024 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 4 Jan 2024filed 8 Jan 2024 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —9,325 | filing |
| 17 Apr 2023filed 20 Apr 2023 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 4 Apr 2023filed 4 Apr 2023 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $8,3983,800 at $2.21 | filing |
| 3 Apr 2023filed 4 Apr 2023 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $11K5,009 at $2.22 | filing |
| 28 Jul 2022filed 1 Aug 2022 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,000 | filing |
| 3 Jan 2022filed 10 May 2022 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,000 | filing |
| 3 Jan 2022filed 5 Jan 2022 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,000 | filing |
| 1 Nov 2021filed 10 May 2022 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $77K3,000 at $25.60 | filing |
| 8 Jan 2020filed 14 Jan 2020 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) & Generate Biomedicines (NASDAQ:GENB)ORMP · tickerreport.com · 11 Oct 2026Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Oramed Pharmaceuticals (NASDAQ:ORMP)ORMP · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Arie Mayer; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.